PASSAGE BIO, INC. (PASG) Current Ratio
- Current ratio · latest quarter: Value 1.22×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.22× | Current assets / current liabilities. $25.18M ÷ $20.72M ≈ 1.22× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 25.18M USD | Assets, Current |
| Current obligations | 20.72M USD | Liabilities, Current |
| Cash and equivalents | 24.16M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 0.00 USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 902.00K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $25.18M | $20.72M | $24.16M | $0.00 | (m) | (m) | $902.00K | (m) | 1.22× |
| 2026-03-31 | $34.74M | $20.10M | $33.34M | $0.00 | (m) | (m) | $1.31M | (m) | 1.73× |
| 2025-12-31 | $47.76M | $23.08M | $46.30M | $0.00 | (m) | (m) | $1.11M | (m) | 2.07× |
| 2025-09-30 | $55.73M | $22.25M | $52.77M | $0.00 | (m) | (m) | $952.00K | (m) | 2.51× |
| 2025-06-30 | $60.31M | $19.80M | $57.63M | $0.00 | (m) | (m) | $2.40M | (m) | 3.05× |
| 2025-03-31 | $66.67M | $17.82M | $63.36M | (m) | (m) | (m) | $1.46M | (m) | 3.74× |
| 2024-12-31 | $78.81M | $19.36M | $37.57M | $39.18M | (m) | (m) | $742.00K | (m) | 4.07× |
| 2024-09-30 | $87.22M | $16.95M | $32.29M | $52.53M | (m) | (m) | $1.49M | (m) | 5.15× |
| 2024-06-30 | $95.00M | $12.38M | $24.77M | $67.00M | (m) | (m) | $621.00K | (m) | 7.67× |
| 2024-03-31 | $108.29M | $12.84M | $36.77M | $67.75M | (m) | (m) | $1.69M | (m) | 8.43× |
| 2023-12-31 | $117.96M | $16.34M | $21.71M | $92.58M | (m) | (m) | $1.30M | (m) | 7.22× |
| 2023-09-30 | $135.71M | $19.81M | $33.58M | $99.20M | (m) | (m) | $2.75M | (m) | 6.85× |
| 2023-06-30 | $153.63M | $19.87M | $30.29M | $121.19M | (m) | (m) | $3.38M | (m) | 7.73× |
| 2023-03-31 | $171.62M | $17.24M | $33.37M | $134.40M | (m) | (m) | $3.03M | (m) | 9.95× |
| 2022-12-31 | $197.04M | $18.35M | $34.60M | $155.01M | (m) | (m) | $4.07M | (m) | 10.74× |
| 2022-09-30 | $222.52M | $21.62M | $62.57M | $151.19M | (m) | (m) | $4.51M | (m) | 10.29× |
| 2022-06-30 | $250.58M | $27.13M | $91.13M | $148.12M | (m) | (m) | $8.21M | (m) | 9.24× |
| 2022-03-31 | $283.00M | $27.48M | $101.61M | $165.48M | (m) | (m) | $9.13M | (m) | 10.30× |
| 2021-12-31 | $325.07M | $29.50M | $128.97M | $186.81M | (m) | (m) | $9.45M | (m) | 11.02× |
| 2021-09-30 | $366.47M | $22.25M | $162.89M | $191.51M | (m) | (m) | $8.98M | (m) | 16.47× |
| 2021-06-30 | $418.84M | $31.25M | $215.46M | $192.34M | (m) | (m) | $16.40M | (m) | 13.40× |
| 2021-03-31 | $450.95M | $19.47M | $249.52M | $188.07M | (m) | (m) | $6.25M | (m) | 23.16× |
| 2020-12-31 | $317.18M | $21.18M | $135.00M | $169.81M | (m) | (m) | $5.26M | (m) | 14.98× |
| 2020-09-30 | $349.51M | $19.10M | $200.57M | $135.13M | (m) | (m) | $3.44M | (m) | 18.30× |
| 2020-06-30 | $368.23M | $14.13M | $353.42M | (m) | (m) | (m) | $7.21M | (m) | 26.05× |
| 2020-03-31 | $382.09M | $5.23M | $366.83M | (m) | (m) | (m) | $2.53M | (m) | 73.09× |
| 2019-12-31 | $165.78M | $3.68M | $158.87M | (m) | (m) | (m) | $629.00K | (m) | 45.04× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |